The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 346:1026-1027 March 28, 2002 Number 13
NextNext

Protease Inhibitors and Mortality among Children and Adolescents Infected with HIV-1

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: The article by Gortmaker et al. about combination therapy including protease inhibitors in children with human immunodeficiency virus type 1 (HIV-1) infection (Nov. 22 issue)1 includes no data about the side effects of protease inhibitors. The homology of the catalytic region of HIV protease with cytoplasmic retinoic acid–binding protein 1 and low-density lipoprotein receptor–related protein may allow protease inhibitors to interfere with these proteins, which may be the cause of the metabolic and somatic alterations that develop in patients treated with protease inhibitors (dyslipidemia, insulin resistance, and lipodystrophy).2 There is also evidence that protease inhibitors directly inhibit . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.